Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

TScan Therapeutics (TCRX) Return on Assets (2021 - 2025)

TScan Therapeutics (TCRX) has disclosed Return on Assets for 5 consecutive years, with 0.23% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Assets rose 12.0% to 0.23% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.23%, a 12.0% increase, with the full-year FY2025 number at 0.43%, down 4.0% from a year prior.
  • Return on Assets was 0.23% for Q4 2025 at TScan Therapeutics, up from 0.25% in the prior quarter.
  • In the past five years, Return on Assets ranged from a high of 0.23% in Q4 2025 to a low of 0.39% in Q1 2023.
  • A 5-year average of 0.32% and a median of 0.33% in 2022 define the central range for Return on Assets.
  • Peak YoY movement for Return on Assets: dropped -13bps in 2022, then rose 12bps in 2025.
  • TScan Therapeutics' Return on Assets stood at 0.25% in 2021, then tumbled by -46bps to 0.36% in 2022, then increased by 13bps to 0.32% in 2023, then fell by -11bps to 0.35% in 2024, then soared by 34bps to 0.23% in 2025.
  • Per Business Quant, the three most recent readings for TCRX's Return on Assets are 0.23% (Q4 2025), 0.25% (Q3 2025), and 0.31% (Q2 2025).